Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK

The imidazolium compound YM155, first discovered as a potent inhibitor of Survivin, effectively kills many carcinomas in preclinical models. However, the upstream signaling mechanism triggered by YM155 remains unclear. Here we studied early signaling responses in vitro in prostate and renal cancer c...

Descripción completa

Detalles Bibliográficos
Autores principales: Danielpour, David, Gao, Zhaofeng, Zmina, Patrick M., Shankar, Eswar, Shultes, Benjamin C., Jobava, Raul, Welford, Scott M., Hatzoglou, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687778/
https://www.ncbi.nlm.nih.gov/pubmed/31395901
http://dx.doi.org/10.1038/s41598-019-47573-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687778/
https://www.ncbi.nlm.nih.gov/pubmed/31395901
http://dx.doi.org/10.1038/s41598-019-47573-y

Ejemplares similares